SWOG S1800D: A Phase II/III Study of N-803 (ALT-803) Plus Pembrolizumab Versus Standard of Care in Participants With Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated With Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study)

Objective

This phase II/III Lung-MAP trial studies how well immunotherapy treatment with N-803 (ALT-803) and pembrolizumab working in treating patients with non-small cell lung cancer that has spread to other places in the body (advanced). Natural killer cells, part of our immune system, are always on alert and ready to defend our bodies from many kinds of infection or rogue cells, such as those that cause cancer. N-803 (ALT-803) may activate natural killer cells so that they can stimulate an immune response to help fight cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving N-803 (ALT-803) and pembrolizumab may help shrink and stabilize lung cancer or prevent it from returning.

https://clinicaltrials.gov/ct2/show/NCT05096663

Location: Essentia Health Cancer Centers

Research Study Categories

  • Adult Studies

Specialty

  • Lung Cancer
Contact
Cancer Clinical Trials at 218-786-3308
or cancertrials@essentiahealth.org

Like most websites, we use cookies and other technologies to keep our website reliable, secure, and to better understand how our site is used. By using our site, you agree to our use of these tools. Learn more.